Lithium research and therapy needs to be continually re-evaluated on the basis of modern methodological approaches in order to shed new light on the mechanism of action and to improve therapeutic use. This book. based on the proceedings of the "International Meeting on Lithium and Rubidium Therapy" held in Venice from September 30th to October 2nd 1983. is devoted to current trends in the pharmacology and clinical aspects of lithium and of a newly born therapeutic cation. rubidium. The first part of this volume deals with modern trends in behavioural and biochemical approaches to the mechanism…mehr
Lithium research and therapy needs to be continually re-evaluated on the basis of modern methodological approaches in order to shed new light on the mechanism of action and to improve therapeutic use. This book. based on the proceedings of the "International Meeting on Lithium and Rubidium Therapy" held in Venice from September 30th to October 2nd 1983. is devoted to current trends in the pharmacology and clinical aspects of lithium and of a newly born therapeutic cation. rubidium. The first part of this volume deals with modern trends in behavioural and biochemical approaches to the mechanism of action of lithium. A larger consideration is reserved for lithium therapy from a clinical point of view and includes re-assessment of long-term treatment with regard to serum levels. biological and psychological predictors. side-effects and new therapeutic uses. A smaller section is concerned with some recent clinical studies on rubidium. This volume should be an invaluable aid to all psychiatrists and those who work in the field of research of these pharmacological active metals. G. U. Corsini List of contributors A. ALCIATI L. BELLODI Institute of Clinical Psychiatry Institute of Clinical Psychiatry University of Milan University of Milan Milan Milan Italy Italy R. H. BELMAKER A. AMDISEN Jerusalem Mental Health Center Psychopharmacology Research Unit Ezrath Nashim Aarhus University, Jerusalem Psychiatric Hospital.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
I: Introduction and Historical Review.- 1 Recent developments in lithium treatment and research.- 2 Lithium treatment of mania and depression over one hundred years.- II: Mechanism of Action of Lithium and Rubidium.- 3 Some recent and some not-so-recent findings on the behavioural effects of lithium in animals.- 4 Opposite effects of lithium and rubidium on neurohormone-stimulated cyclic AMP accumulation in rat brain.- 5 The effect of rubidium and lithium on adenylate cyclase and neurotransmitter receptors.- 6 Does lithium prevent the development of dopamine receptor supersensitivity? Behavioural studies.- III: Clinical Aspects of Long-Term Lithium Treatment.- 7 Critical issues in the evaluation of long-term lithium treatment.- 8 A prospective study of long-term lithium treatment. An interim report.- 9 Lithium dosage and prophylaxis. A double-blind controlled study.- 10 Lithium discontinuation in bipolar illness: a double-blind prospective controlled study.- 11 Lithium treatment in schizoaffective patients.- 12 Static and kinetic study of the RBC/plasma lithium ratio in manic-depressive, schizoaffective and schizophrenic patients in thymic remission: significance for diagnosis and monitoring.- 13 Lithium prophylaxis in major affective disorders: on the specificity and sensitivity of some "new" predictors of treatment outcome.- 14 Practical value of biological and psychological indicators in predicting response to lithium prophylaxis of manic-depressive psychosis.- 15 Outcome to treatment with lithium in affective patients and family history.- 16 Antidepressant-induced switch and outcome to lithium prophylaxis in bipolar patients.- IV: Clinical Aspects of Long-Term Rubidium Treatment.- 17 Rubidium salts in depressed patients. An open pilot study using standardizedtechniques.- 18 Preliminary results with rubidium in depressed patients.- 19 The use of rubidium chloride in depressive disorders: clinical aspects.- V: New Aspects in Lithium and Rubidium Treatment.- 20 The effect of lithium treatment in humans of psychophysiological increases and decreases in heart rate.- 21 Left ventricular performance following lithium treatment.- 22 Lithium carbonate and granulocyte function during cancer chemotherapy. Preliminary report.- 23 Cancer chemotherapy induced neutropenia: effects of lithium carbonate.- 24 Lithium and rubidium compounds in cluster headache: overview and perspectives.- 25 Lithium therapy in cluster headache. Effect on iris neuro-muscular junction.- 26 Changes in tubular enzymes during acute lithium treatment.- 27 Prophylactic efficacy of carbamazepine in lithium-resistant affective disorders.
I: Introduction and Historical Review.- 1 Recent developments in lithium treatment and research.- 2 Lithium treatment of mania and depression over one hundred years.- II: Mechanism of Action of Lithium and Rubidium.- 3 Some recent and some not-so-recent findings on the behavioural effects of lithium in animals.- 4 Opposite effects of lithium and rubidium on neurohormone-stimulated cyclic AMP accumulation in rat brain.- 5 The effect of rubidium and lithium on adenylate cyclase and neurotransmitter receptors.- 6 Does lithium prevent the development of dopamine receptor supersensitivity? Behavioural studies.- III: Clinical Aspects of Long-Term Lithium Treatment.- 7 Critical issues in the evaluation of long-term lithium treatment.- 8 A prospective study of long-term lithium treatment. An interim report.- 9 Lithium dosage and prophylaxis. A double-blind controlled study.- 10 Lithium discontinuation in bipolar illness: a double-blind prospective controlled study.- 11 Lithium treatment in schizoaffective patients.- 12 Static and kinetic study of the RBC/plasma lithium ratio in manic-depressive, schizoaffective and schizophrenic patients in thymic remission: significance for diagnosis and monitoring.- 13 Lithium prophylaxis in major affective disorders: on the specificity and sensitivity of some "new" predictors of treatment outcome.- 14 Practical value of biological and psychological indicators in predicting response to lithium prophylaxis of manic-depressive psychosis.- 15 Outcome to treatment with lithium in affective patients and family history.- 16 Antidepressant-induced switch and outcome to lithium prophylaxis in bipolar patients.- IV: Clinical Aspects of Long-Term Rubidium Treatment.- 17 Rubidium salts in depressed patients. An open pilot study using standardizedtechniques.- 18 Preliminary results with rubidium in depressed patients.- 19 The use of rubidium chloride in depressive disorders: clinical aspects.- V: New Aspects in Lithium and Rubidium Treatment.- 20 The effect of lithium treatment in humans of psychophysiological increases and decreases in heart rate.- 21 Left ventricular performance following lithium treatment.- 22 Lithium carbonate and granulocyte function during cancer chemotherapy. Preliminary report.- 23 Cancer chemotherapy induced neutropenia: effects of lithium carbonate.- 24 Lithium and rubidium compounds in cluster headache: overview and perspectives.- 25 Lithium therapy in cluster headache. Effect on iris neuro-muscular junction.- 26 Changes in tubular enzymes during acute lithium treatment.- 27 Prophylactic efficacy of carbamazepine in lithium-resistant affective disorders.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826